Figure 33.
Kaplan-Meier survival curves demonstrating trend towards increased colectomy ((a), p = 0.06) and UC-related hospitalization ((b), p = 0.02) rate during maintenance infliximab or adalimumab for 57 ulcerative colitis patients starting anti-TNF therapy within three years of diagnosis (blue) compared to 58 patients starting anti-TNF therapy more than three years after diagnosis (red). Hashed lines indicate censored cases (did not meet primary outcome to last follow-up).